Drug Repurposing for Hematological Malignancies

Michael, Antony Anista; Balakrishnan, Pavithra; Velusamy, Thirunavukkarasu

doi:10.1007/978-981-19-5399-6_11

Cited by 2 publications

(2 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the field of hematological malignancies, despite the introduction of drug repurposing, which presents new possibilities for innovative treatments, achieving complete remission remains an arduous task ( 62 ). Clinical trials that explore the repurposing of drugs in oncology have exhibited varying levels of success, with certain limitations such as limited sample sizes and participant heterogeneity ( 63 ).…”

Section: Challenges In Cancer Endeavormentioning

confidence: 99%

“…One such instance involves the repurposing of bortezomib to target hematological malignancies. However, this drug proved to be ineffective as a stand-alone treatment for other malignancies, including acute myelogenous leukemia (AML) ( 62 ). Another example that showcases the act of appropriating preexisting resources for alternative purposes pertains to the potential drawbacks that arise when repurposing the chemical compound valproic acid (VPA) for various medical applications.…”

Section: Challenges In Cancer Endeavormentioning

confidence: 99%

See 1 more Smart Citation

The dark side of drug repurposing. From clinical trial challenges to antimicrobial resistance: analysis based on three major fields

Natsheh,

Alsaleh,

Alkhawaldeh

et al. 2024

dti

View full text Add to dashboard Cite

Drug repurposing is a strategic endeavor that entails the identification of novel therapeutic applications for pharmaceuticals that are already available in the market. Despite the advantageous nature of implement- ing this particular strategy owing to its cost-effectiveness and efficiency in reducing the time required for the drug discovery process, it is essential to bear in mind that there are various factors that must be meticulously considered and taken into account. Up to this point, there has been a noticeable absence of comprehensive analyses that shed light on the limitations of repurposing drugs. The primary aim of this review is to con- duct a thorough illustration of the various challenges that arise when contemplating drug repurposing from a clinical perspective in three major fields cardiovascular, cancer and diabetes and to further underscore the potential risks associated with the emergence of antimicrobial resistance when employing repurposed antibiotics for the treatment of noninfectious and infectious diseases. The process of developing repurposed medications necessitates the application of creativity and innovation in designing the development program, as the body of evidence may differ for each specific case. In order to effectively repurpose drugs, it is crucial to consider the clinical implications and potential drawbacks that may arise during this process. By com- prehensively analyzing these challenges, we can attain a deeper comprehension of the intricacies involved in drug repurposing, which will ultimately lead to the development of more efficacious and safe therapeutic approaches.

show abstract

Section: Challenges In Cancer Endeavormentioning

confidence: 99%

Section: Challenges In Cancer Endeavormentioning

confidence: 99%

The dark side of drug repurposing. From clinical trial challenges to antimicrobial resistance: analysis based on three major fields

Natsheh,

Alsaleh,

Alkhawaldeh

et al. 2024

dti

View full text Add to dashboard Cite

show abstract

Repurposed Medicines: A Scan of the Non‐commercial Clinical Research Landscape

Akinbolade,

Fairbairn,

Inskip

et al. 2024

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Medicine repurposing is a strategy to identify new uses for the existing medicines for the purpose of addressing areas of unmet medical need. This paper aims to provide horizon scanning intelligence on repurposed medicines that are evaluated by non‐commercial organizations such as academia and highlights opportunities for further research to improve patient health outcomes. A scan of the clinical landscape of non‐commercially sponsored repurposed medicines is routinely conducted by the NIHR Innovation Observatory (IO). This ongoing project involves a horizon scan of clinical trial registries and the IO's internal horizon scanning Medicines Innovation Database to identify potential candidate medicines used as monotherapy or in combination to treat new indications outside the scope of their licensed indication. In addition to making these data publicly available, the output also supports the NHS England Medicines Repurposing Programme. The snapshot scan reported here (trials completing April 2020–March 2023) identified a total of 528 technologies (meaning, a single product or combination of medicinal products targeting a specific indication in one or more related trials). The technologies were classified according to their characteristics and targeted therapeutic indications as well as revealing the least treated disease conditions. The candidate medicines identified in this scan could potentially receive tailored support toward adoption into practice and policy. The NIHR IO regularly provides this scan as a source of intelligence on repurposed medicines. This provides valuable insights into innovation trends, gaps, and areas of unmet clinical need.

show abstract

Drug Repurposing for Hematological Malignancies

Cited by 2 publications

References 91 publications

The dark side of drug repurposing. From clinical trial challenges to antimicrobial resistance: analysis based on three major fields

The dark side of drug repurposing. From clinical trial challenges to antimicrobial resistance: analysis based on three major fields

Repurposed Medicines: A Scan of the Non‐commercial Clinical Research Landscape

Contact Info

Product

Resources

About